Skip to content

This Site is Intended for Healthcare Professionals Only

Search AI Powered

Latest Stories

Recall report of blood pressure drugs 'misleading'

The Royal Pharmaceutical Society (RPS) has confirmed that the recall of blood pressure drugs amlodipine and olmesartan by the Food and Drug Administration is only for the US market and will not have any impact in the UK.

MHRA also clarified that the manufacturer of these drugs, Macleod Pharmaceuticals, does not supply amlodipine medicines in the UK.

It was published online in both the Daily Record and Daily Express on the morning of Monday, March 21, that the drugs had been recalled in the US by the FDA due to deviations from standard manufacturing protocols by the manufacturer.


RPS intervened to ensure the articles were edited to make clear that this is not an issue in the UK after confirmation from the MHRA. Amlodipine tablets from Macleod Pharmaceuticals aren't available for wholesale distribution in the UK.

An MHRA statement said: “The MHRA has confirmed that the recall of combined Amlodipine/Olmesartan Medoxomil tablets 10 mg/20 mg, batch number BAD62101A (expiry Feb 24), is for the US market only – while Macleods Pharma does supply other medicines to the UK, this particular product is not available here.”

"Patients seeking advice can be reassured that the amlodipine and olmesartan provided by the NHS is not affected by the recall in the USA," assures RPS.

More For You

NHS app to boost clinical trials

The focus is on encouraging people from underrepresented groups, including minorities from African and Asian heritage, to sign up for clinical trials.

iStock

Government to use NHS app to boost clinical trials

The government’s 10-Year Health Plan is expected to provide a fillip to clinical trials, and it plans to make use of the NHS App to encourage people to sign up as participants.

People will be able to sign up for the NIHR Be Part of Research service (bepartofresearch.uk) on the NHS App for the trials best suited to their interests and needs.

Keep ReadingShow less
US pharma bets big on China to snap up potential blockbuster drugs

Through June, US drugmakers have signed 14 deals potentially worth $18.3 billion to license drugs from China-based companies

US pharma bets big on China to snap up potential blockbuster drugs

US drugmakers are licensing molecules from China for potential new medicines at an accelerating pace, according to new data, betting they can turn upfront payments of as little as $80 million into multibillion-dollar treatments.

Through June, US drugmakers have signed 14 deals potentially worth $18.3 billion to license drugs from China-based companies. That compares with just two such deals in the year-earlier period, according to data from GlobalData provided exclusively to Reuters.

Keep ReadingShow less
Alliance Healthcare team raises thousands with charity bike ride to Paris

The Alliance Healthcare team

Alliance Healthcare team raises thousands with charity bike ride to Paris

Eight Alliance Healthcare team members raised over £55,000 for Theodora Children’s Charity by cycling from Surrey to Paris.

From June 13th-15th, the team took on the gruelling 300 mile cross-border Tour D’Alliance 2025 challenge and raised vital funds to support children who may be living with serious health challenges through Theodora Children’s Charity’s Giggle Doctor programme.

Keep ReadingShow less
Over four million flu vaccines across England in the 2024/25 winter flu season.

Over four million flu vaccines across England in the 2024/25 winter flu season.

CCA release

Community pharmacy administered over four million flu vaccines

Community pharmacy administered over four million flu vaccines across England in the 2024/25 winter flu season, the highest outside of the pandemic, according to the Company Chemists’ Association.

This is nearly 10 per cent higher than the number of flu vaccines administered in 2023/24.

Keep ReadingShow less
Chemotherapy-free leukaemia treatment

The trial found that a combination of two cancer drugs, ibrutinib and venetoclax, could perform better than chemotherapy among patients with chronic lymphocytic leukaemia.

iStock

Chemotherapy-free leukaemia treatment shows promise during trial

In a breakthrough in leukaemia research, scientists in the UK have tested a chemotherapy-free approach, involving a combination of targeted drugs, which may offer better outcomes.

The new treatment could radically change the way chronic lymphocytic leukaemia (CLL), the most common form of leukaemia in adults, is treated.

Keep ReadingShow less